| Document |
Document Title |
|
WO/2002/014513A1 |
Use of a polypeptide having a ligand activity to sensory epithelium neuropeptide-like receptor (SENR) which is a G protein-coupled receptor protein and DNA encoding the same. Drugs against attention deficit disorder or narcolepsy contain...
|
|
WO/2002/012169A1 |
The invention relates to novel amino diphenyl ethers and amido diphenyl ethers, to methods for the production thereof, and to their use in medicaments, especially for the indications of arteriosclerosis and hypercholesterolemia.
|
|
WO/2002/012196A2 |
Lactam inhibitors are provided which have the structure (I), x is (a) or (b) wherein Y is O or S and R?4¿ is (i), (ii) or R?8¿ at least one of R?1¿ and R?2¿ is hydrogen, and R?1¿, R?2¿, R?3¿, R?5¿, R?6¿, R?7¿, and R?8¿, are as...
|
|
WO/2002/010146A1 |
Compounds of formula (I) in which: each A is independently hydrogen, C¿1-6?alkyl optionally substituted by hydroxyl, C¿1-6?alkoxy, C¿1-6?alkenyl or C¿1-6?acyl group or a halogen atom or hydroxyl, CN or CF¿3? group; R3 is hydrogen, m...
|
|
WO/2002/010139A1 |
Iminoazepinyl Hexanoic Acid derivatives of formula (I) as well as pharmaceutically acceptable salts and derivatives thereof useful in the inhibition of the inducible isoform of nitric oxide synthase for the treatment of arthritis, osteoa...
|
|
WO/2002/006220A1 |
Free-flowing flakes of vinyl caprolactam monomer usable below its melting point of 34°C without developing coloration.
|
|
WO/2002/006232A1 |
This invention provides compounds of Formula (I) wherein: R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, T, T?1¿, T?2¿, and X are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting me...
|
|
WO/2002/006241A1 |
There is disclosed a compound having the formula or a pharmaceutically acceptable salt thereof, wherein: R¿1a?, R¿1b? and R¿1c? are independently fluorine or hydrogen; R¿2? is C¿1? to C¿12? alkyl being straight or branched chain, s...
|
|
WO/2002/002520A2 |
The present invention is disubstituted amines of formula (I) and disubstituted amines of formula (II) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2002/002512A2 |
The present invention is substituted amines of formula (X) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2002/002530A1 |
A novel GPR14 antagonist. The GPR14 antagonist comprises a compound represented by the formula (I) or a salt thereof wherein Ar represents optionally substituted aryl; X represents a spacer; n is an integer of 1 to 10; R represents an op...
|
|
WO/2002/002531A1 |
The invention is directed to nonpeptide substituted benzodiazepines of Formula I, wherein A, X, n, R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for...
|
|
WO/2002/000626A1 |
Compounds according to general formulae (1 and 2), wherein G?1¿ is an azepine derivative and G?2¿ is a group according to general formulae (9 - 11) are new. Compounds according to the invention are vasopressin V¿2? receptor agonists. ...
|
|
WO/2001/098273A1 |
The invention provides compounds of general formula (I) wherein m, n, Q, Z?1¿, Z?2¿, R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿, R?7¿ and R?8¿ are as defined in the specification, processes for their preparation, pharmaceutical composi...
|
|
WO/2001/096294A1 |
The invention relates to a method for the production of caprolactam from a compound of formula (I): NC-(CH¿2?)¿5?-CO-R where R = a carboxamido, carboxlic acid or carboxylate ester group, characterised in that a) a compound (I), or mixt...
|
|
WO/2001/095911A1 |
The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, n...
|
|
WO/2001/095856A2 |
The present invention relates to a novel urea derivative which is useful as an anti-cancer agent, its pharmaceutically acceptable acid addition salt or stereoisomer, and to a process for preparing the urea derivative and an anti-cancer c...
|
|
WO/2001/096331A1 |
Lactam inhibitors are provided which have the structure (I) including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is l to 5; and R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?,...
|
|
WO/2001/094294A1 |
Fungicidal compounds of formula (I), wherein R¿1? represents (CH¿2?)¿n?R¿3?, where n represents an integer from 5 to 10 inclusive and R¿3? represents H, optionally substituted phenyl, optionally substituted phenoxy or optionally sub...
|
|
WO/2001/093840A2 |
The invention relates to the use of cyclic compounds as ligands of integrin receptors, in particular as ligands of the $g(a)¿v?ß¿3? integrin receptor. The invention also relates to the novel compounds, to the use thereof and to pharma...
|
|
WO/2001/094304A1 |
A process for the production of sulfonic ester derivatives of the general formula (4) or (5) by reacting an amino alcohol of the general formula (1) or (2) with an organic sulfonyl halide of the general formula (3) in a mixed solvent of ...
|
|
WO/2001/094308A1 |
The invention relates to a method for separating ammonia from solutions (I) containing lactam and ammonia by distillation. The method is characterized in that the separation takes place in a distillation device (a) at an absolute pressur...
|
|
WO/2001/092226A1 |
One aspect of the present invention relates to novel heterocyclic compounds, such as Formula (1). A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, ...
|
|
WO/2001/092235A1 |
This invention relates to novel lactams having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the pr...
|
|
WO/2001/090082A1 |
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula (1) wherein one of X, Y, or Z is independently -S-, -O-, or > N-R?4¿, the others are-CH¿2-;? (p) is an i...
|
|
WO/2001/090065A1 |
The invention concerns a method for purifying lactams, more particularly lactams obtained by cyclizing hydrolysis of aminonitrile. More particularly, the invention concerns the purification of $g(e)-caprolactam obtained by cyclizing hydr...
|
|
WO/2001/089451A2 |
The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment...
|
|
WO/2001/090081A1 |
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula (I) wherein one of X, Y or Z is independently -S-,-0- CH¿2?- or $m(g)N-R?6¿, the others are -CH¿2?-; m ...
|
|
WO/2001/087299A1 |
The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is admin...
|
|
WO/2001/087834A1 |
A melanin-concentrating hormone antagonist which contains a compound represented by the formula or a salt thereof: (I) wherein R represents hydrogen, halogeno, or an optionally substituted cyclic group; X represents a bond or a spacer in...
|
|
WO/2001/085696A1 |
The use of a compound of formula (I) in free form or in the form of a pharmaceutically acceptable salt for the preparation of a medicament for use in the treatment of rhinitis, wherein R?1¿ is phenyl that is unsubstituted or is substitu...
|
|
WO/2001/085697A1 |
The present invention relates to certain substituted caporlactam carbonate and ether compounds of following formula (I): pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process...
|
|
WO/2001/085695A1 |
Tetrahydroisoquinoline analogs are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strengt...
|
|
WO/2001/083444A1 |
The invention relates to a method for producing cyclic lactams of the formula (II), wherein n and m may each represent 0, 1, 2, 3, 4, 5, 6, 7, 8 and 9 and the sum of n + m is at least 3, preferably at least 4, R?1¿ and R?2¿ represent C...
|
|
WO/2001/083442A1 |
The invention relates to a method for producing caprolactam, characterized in that a) a mixture (I) containing 6-aminocapronitrile and water in the liquid phase is converted into a mixture (II) containing caprolactam, ammonia, water, hig...
|
|
WO/2001/083443A1 |
The invention relates to a method for producing caprolactam, which is characterized by a) reacting, in the presence of a catalyst, a mixture (I) that contains 6-aminocapronitrile and water in the gaseous phase to give a mixture (II) that...
|
|
WO/2001/083441A1 |
The invention relates to a method for producing cyclic lactams of formula (II) by reacting a compound (I) of formula (I) with water in the presence of an organic, liquid dilution agent in the liquid phase. In formula (II), n and m respec...
|
|
WO/2001/081349A1 |
A novel, optically active, quaternary ammonium salt with axial asymmetry which is useful as a phase-transfer catalyst with which a glycine derivative is stereoselectively alkylated to convert it into an optically active $g(a)-amino acid ...
|
|
WO/2001/079176A1 |
The present invention relates to a process for the preparation of 3-[(1'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[1]-ben
zazepine, whose derivatives are angiotensin-converting enzyme (ACE) inhibitors useful in the treatment of hype...
|
|
WO/2001/079172A1 |
The invention concerns a compound of formula (I) wherein: G represents a phenyl or a heterocycle optionally substituted; G¿1? and G¿2? being N or C; T¿1? represents -CH¿2?-CH¿2?-, -CH=CH-, =CH-CH¿2?-; and T¿2? is a bond or T¿1? r...
|
|
WO/2001/077086A1 |
This invention relates to novel lactams of Formula (I) having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more sp...
|
|
WO/2001/077068A2 |
A process for the production of 6-aminocaproamide comprising reacting 5-cyanovaleramide with hydrogen in the presence of a metal catalyst. The 6-aminocaproamide is useful, for example, in the production of caprolactam and nylon 6.
|
|
WO/2001/074348A2 |
Vasopeptidase inhibitors, especially omapatrilat, are useful in treating isolated systolic hypertension. The vasopeptidase inhibitor may be used in combination with other pharmaceutically active agents.
|
|
WO/2001/074783A1 |
This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically...
|
|
WO/2001/074784A1 |
This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit t...
|
|
WO/2001/072707A2 |
This invention provides caspase inhibitors of formula (I): wherein Z is oxygen or sulfur; R?1¿ is hydrogen, -CHN¿2?,R, CH¿2?OR, CH¿2?SR, or -CH¿2?Y; Y is an electronegative leaving group; R?2¿ is CO¿2?H, CH¿2?CO¿2?H, or esters, ...
|
|
WO/2001/072697A2 |
Process to prepare a 5-cyanovaleric acid or its ester by carbonylation of a pentenenitrile, wherein pentenenitrile is reacted with carbon monoxide and water or an alcohol in the presence of a catalyst system. The catalyst system comprise...
|
|
WO/2001/072673A1 |
Anthracene derivatives of the general formula (I); and organic electroluminescent(EL) devices each having at least an organic light-emitting layer sandwiched between a pair of electrodes and containing the derivatives [wherein X and Y ar...
|
|
WO/2001/070677A1 |
A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures of formula (I) (where the variables are as defined in the claims). The compounds are inhibitors of $g(g)-secretase, and hence are usef...
|
|
WO/2001/070673A2 |
The present application describes novel cyclic $g(b)-amino acid derivatives of formula (I) or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O,...
|
